Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.
Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
Type:
Application
Filed:
October 7, 2011
Publication date:
February 2, 2012
Inventors:
David C. YEOMANS, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
Abstract: A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function.
Type:
Application
Filed:
June 10, 2011
Publication date:
January 12, 2012
Inventors:
Alexander M. Schobel, Garry L. Myers, Keith Joseph Kendall, Thomas Rademacher, Jan Mous, Justin N. W. Barry, Phillip Williams, Africa Garcia Barrientos
Abstract: substances and the nasal administration thereof, in particular as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, in particular the posterior region of the nasal airway, and in particular the upper posterior region of the nasal airway, which includes the olfactory bulb, in particular in the treatment of neurological conditions and disorders.
Abstract: Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.
Type:
Application
Filed:
June 27, 2011
Publication date:
October 20, 2011
Inventors:
Yun Anthony Joonkyoo, Patrick Yuarn-Bor Lee
Abstract: The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.
Type:
Application
Filed:
June 21, 2011
Publication date:
October 13, 2011
Inventors:
David C. YEOMANS, William H. FREY, II, Daniel I. JACOBS
Abstract: The present invention discloses methods for the diagnosis and treatment of autism. The diagnostic tools provided use analysis of levels of G-protein expression, oxytocin, and vasopressin. Treatment for autism spectrum disorder and symptoms of autism spectrum disorder, especially repetitive behavior, is also provided.
Abstract: A topical pharmacological preparation in the form of cream, suppositories or drops delivered topically to the vagina in order to contract the smooth muscle of the vaginal wall. The preparation contains a smooth muscle contracting agent such as oxytocin capable of constrict the vaginal tube reducing its overall diameter for a more pleasurable sexual experience for the female subject and his partner alike. The smooth muscle contracting agent can be associated with a systemic absorption retardant such as a mixture of Benzyl Alcohol, Acetone and Isopropanol. Such a formulation achieves high local tissue concentration of the smooth muscle contraction substance such as oxytocin in vicinity to the site of application, via minimization of systemic absorption of the smooth muscle contraction inducing substance and at the same time via promotion of its submucosal absorption across the mucosal barrier.
Abstract: A transmembrane fusion protein including ubiquitin or a ubiquitin-like protein, a membrane translocation sequence linked to the C-terminus of the ubiquitin or ubiquitin-like protein, and a biologically active molecule linked to the C-terminus of the membrane translocation sequence is disclosed herein. A polynucleotide encoding the transmembrane fusion protein, a recombinant expression vector including the polynucleotide sequence, a cell transformed by the recombinant expression vector, and a method of delivering the biologically active molecule into a cell using the transmembrane fusion protein are also disclosed.
Abstract: A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.
Abstract: A composition and method for treating a bone condition of an animal. The compostion includes nanoparticles; a targeted moiety covalently bonded to an outer surface of each nanoparticle; and osteoblast stimulating molecules encapsulated within each nanoparticle. The method for treating a bone condition includes introducing the composition into the animal.
Type:
Application
Filed:
October 27, 2010
Publication date:
May 5, 2011
Inventors:
Shaker A. Mousa, Mohammed H. Qari, Mohammed S. Ardawi
Abstract: A pharmaceutical controlled release composition in solid dosage form is provided which comprises (I) a water-swellable linear polymer obtainable by reacting together: (a) a dried polyethylene oxide; (b) a dried C5 to C20 diol; and (c) a Bifunctional diisocyanate; and (II) a releasable pharmaceutically active agent.
Abstract: Improved biodegradable and bioabsorbable BAB-block copolymers exhibiting reverse thermal gellation properties, and aqueous polymer compositions including the BAB-block copolymers, are provided. Methods of making the improved BAB-block copolymers and compositions including the same are also provided.
Type:
Application
Filed:
September 20, 2010
Publication date:
March 24, 2011
Applicant:
Protherics Salt Lake City, Inc.
Inventors:
Kirk D. FOWERS, Ramesh C. RATHI, Ai-Zhi PIAO
Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia compromised lactation conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.
Type:
Application
Filed:
March 30, 2009
Publication date:
February 24, 2011
Applicant:
Ferring B.V.
Inventors:
Sudar Alagarsamy, Robert Galyean, Kazimierz Wisniewski, Claudio Schteingart
Abstract: The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.
Type:
Application
Filed:
July 27, 2010
Publication date:
January 27, 2011
Inventors:
Lawrence R. TOLL, David C. YEOMANS, Martin S. ANGST, Daniel I. JACOBS
Abstract: Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.
Type:
Application
Filed:
September 28, 2007
Publication date:
December 9, 2010
Applicant:
MDRNA, INC.
Inventors:
Alexis Kays Leonard, Joshua O. Sestak, Henry R. Costantino, Anthony P. Sileno, Lalit Raj Peddakota, Kayvon Emile Sharghi, Garland M. Bellamy, Jason Philip Gesty
Abstract: Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants.
Abstract: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.
Abstract: The invention discloses a pharmaceutical composition containing oxytocin and melatonin in amounts therapeutically effective for inducing labor in a pregnant human patient. Preferably, the oxytocin content is reduced to mitigate unwanted side effects and the melatonin content synergistically enhances the oxytocin's labor-inducing effectiveness. Also disclosed is a pharmaceutical composition for treatment of a pregnant human patient experiencing pre-term labor characterized by early expression of melatonin receptors in myometrial cells, the composition containing one or more agents which interfere with melatonin binding to said receptors.